ライフサイエンスコーパス: RSV vaccine

1 the safety and efficacy of a live attenuated RSV vaccine.

2 ion of G and F would be desirable for a live RSV vaccine.

3 candidate for a live attenuated recombinant RSV vaccine.

4 which is the major target population for an RSV vaccine.

5 ecades of RSV research, there is no licensed RSV vaccine.

6 ould be considered when designing a vectored RSV vaccine.

7 lowing vaccination with formalin-inactivated RSV vaccine.

8 tant candidate for inclusion in an effective RSV vaccine.

9 he over 4-decade-long quest for a successful RSV vaccine.

10 significant advance in the development of an RSV vaccine.

11 rove the safety and long-term efficacy of an RSV vaccine.

12 expression with the aim of generating novel RSV vaccines.

13 important for the development of attenuated RSV vaccines.

14 ng 37 1-2-month-old infants-a target age for RSV vaccines.

15 pectively, were evaluated as live-attenuated RSV vaccines.

16 eeded to optimize the safety and efficacy of RSV vaccines.

17 e the risk of enhanced disease with non-live RSV vaccines.

18 ntribute to the design of broadly protective RSV vaccines.

19 V pathogenesis and to assess the efficacy of RSV vaccines.

20 ng such a mutation in future live attenuated RSV vaccines.

21 ll be important in the future development of RSV vaccines.

22 be useful biomarkers of attenuation for live RSV vaccines.

23 ren enrolled in studies of 4 live-attenuated RSV vaccines.

24 ed in vaccine-enhanced disease with previous RSV vaccines.

25 munity induced by the recombinant adenoviral RSV vaccine administered by use of an intramuscular prim

26 RSV vaccine and antibody strategies are likely to be cos

27 ction was not significantly different in the RSV vaccine and placebo groups.

28 mportant target group for the development of RSV vaccines and antivirals.

29 the disease-enhancing potential of candidate RSV vaccines and better understand enhanced disease.

30 logy of RSV and for timing the use of future RSV vaccines and immunoprophylaxis in low- and middle-in

31 ubstantial efforts have been made to develop RSV vaccines and vaccine-like monoclonal antibodies to p

32 pre-F conformation and support its use as an RSV vaccine antigen.

33 us (RSV) is a significant human pathogen, no RSV vaccines are available.

34 However, no RSV vaccines are available.

35 the safety and immunogenicity data of these RSV vaccines are encouraging, low rates of infection mak

36 Experimental live attenuated RSV vaccines are grown in Vero cells, but during product

37 Several promising live-attenuated RSV vaccines are in development.

38 Although there is no safe and effective RSV vaccine available, significant progress has been rec

39 ldren who received minimally attenuated live RSV vaccines but not in children who received highly att

40 We have generated an epitope-specific RSV vaccine by grafting a neutralizing epitope (F-epitop

41 a novel strategy to attenuate a recombinant RSV vaccine by incorporating a low-fusion, subgroup B F

42 mphasize the need to investigate a pediatric RSV vaccine candidate carefully for priming of ERD over

43 /404 parent virus, making it a promising new RSV vaccine candidate created by use of reverse genetics

44 ) to produce the recombinant live-attenuated RSV vaccine candidate DeltaNS2/Delta1313.

45 re underscore the need to evaluate a nonlive RSV vaccine candidate during preclinical development ove

46 ve reported that a virus-like particle (VLP) RSV vaccine candidate stimulated, in mice, robust, prote

47 This provides an improved vectored RSV vaccine candidate suitable for pediatric clinical ev

48 Overall, this report describes a potential RSV vaccine candidate that merits further evaluation in

49 comparable to that of MEDI-559, a promising RSV vaccine candidate that presently is in clinical tria

50 rA2cp248/404/1030 Delta SH is the first RSV vaccine candidate to be sufficiently attenuated in y

51 ed version of this promising live-attenuated RSV vaccine candidate, this study demonstrated the prope

52 m of the RSV F protein represent a promising RSV vaccine candidate.

53 Ps has the potential to produce a successful RSV vaccine candidate.

54 tential of virus-like particles (VLPs) as an RSV vaccine candidate.

55 ur data indicated that PIV5/F is a promising RSV vaccine candidate.IMPORTANCE A safe and efficacious

56 Currently, several RSV vaccine candidates are under development to target d

57 We designed new live attenuated RSV vaccine candidates by codon-pair deoptimization (CPD

58 ron- alpha / beta response, was deleted from RSV vaccine candidates by use of reverse genetics.

59 e of RSV in bacterial OM and the efficacy of RSV vaccine candidates designed to provide mucosal and c

60 tenuating mutations in new, live recombinant RSV vaccine candidates for both pediatric and elderly po

61 d Abs can be readily induced in mice by live RSV vaccine candidates in the presence of physiologic le

62 genicity and efficacy of two live attenuated RSV vaccine candidates of different level of attenuation

63 However, NS2-deleted RSV vaccine candidates rendered RSV overattenuated or po

64 loped two parainfluenza virus 5 (PIV5)-based RSV vaccine candidates that protect mice against RSV cha

65 Most importantly, we found that PIV5-based RSV vaccine candidates were efficacious in preventing lo

66 Three NS2 gene-deleted RSV vaccine candidates were studied: rA2cp Delta NS2, rA

67 Two live attenuated, recombinantly derived RSV vaccine candidates, rA2cp248/404 Delta SH and rA2cp2

68 oing obstacle for the development of nonlive RSV vaccine candidates.

69 lusion in future live attenuated recombinant RSV vaccine candidates.

70 ed into foreign VLP systems to generate anti-RSV vaccine candidates.

71 in mice, in contrast to other nonreplicating RSV vaccine candidates.

72 optimized human respiratory syncytial virus (RSV) vaccine candidates in the context of strong selecti

73 binant chimeric respiratory syncytial virus (RSV) vaccine consisting of the extramembrane domains of

74 sults have important implications for future RSV vaccine design, suggesting that enhancing a Th1 resp

75 t IFN-alpha is a promising target for future RSV vaccine design.

76 cell responses is important to consider for RSV vaccines designed for young infants.

77 The difficulties involved in RSV vaccine development were recognized in an early vacc

78 sequently focus on the promising pipeline of RSV vaccine development.

79 Respiratory syncytial virus (RSV) vaccine development for direct protection of young

80 inform selection of clinical end points for RSV vaccine efficacy trials.

81 nogenicity of an adenovirus serotype 5-based RSV vaccine encoding the fusion (F) protein (Ad5.RSV-F)

82 These measures of RSV vaccine-enhanced disease are dependent upon STAT4.

83 RSV vaccine-enhanced disease can be mimicked in BALB/c m

84 ever, the role of FasL in the development of RSV vaccine-enhanced disease has not been elucidated.

85 after RSV challenge that closely mimics the RSV vaccine-enhanced disease observed in humans.

86 The underlying causes of RSV vaccine-enhanced disease remain poorly understood.

87 s elicited by RSV G are not the basis for FI-RSV vaccine-enhanced disease.

88 understanding the mechanisms attributable to RSV vaccine-enhanced disease.

89 pulmonary eosinophil response related to FI-RSV vaccine-enhanced disease.

90 effector CD4 T cells and the development of RSV vaccine-enhanced disease.

91 otection and are not solely the basis for FI-RSV vaccine-enhanced illness.

92 on grants these cells the ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia.

93 pathogenesis of respiratory syncytial virus (RSV) vaccine-enhanced disease in the mouse model.

94 The PIV3-vectored RSV vaccines evaluated here further underscore the utili

95 Presently, no safe and efficacious RSV vaccine exists; however, advances in our understandi

96 ously vaccinated with a formalin-inactivated RSV vaccine experienced enhanced morbidity and mortality

97 lin-inactivated respiratory syncytial virus (RSV) vaccine experienced enhanced disease and exhibited

98 -inactivated respiratory syncytial virus (FI-RSV) vaccine experienced enhanced respiratory disease, i

99 s (a formalin-inactivated, alum-precipitated RSV vaccine [FI-RSV] given intramuscularly and live RSV

100 An RSV vaccine for infants is still not available.

101 A live attenuated RSV vaccine for the youngest infant will use cpts-248/40

102 ly great enough to justify development of an RSV vaccine for use in this group.

103 V vaccine in the elderly might differ from a RSV vaccine for young children.

104 is incident precluded development of subunit RSV vaccines for infants for over 30 years, because the

105 el itself and to safe development of nonlive RSV vaccines for seronegative infants and children.

106 Neither RSV vaccine formulation had an effect on the humoral res

107 enza vaccine given concomitantly with 1 of 2 RSV vaccine formulations in persons > or =65 years old w

108 ting design and distribution of a successful RSV vaccine globally.

109 ed with a nonlive, formalin-inactivated (FI)-RSV vaccine has been associated with serious enhanced re

110 nd most efforts to develop a live attenuated RSV vaccine have focused on strain A2 or other subgroup

111 the safety and efficacy of a live attenuated RSV vaccine.IMPORTANCE RSV binds to the corresponding ch

112 he immunologic requirements for a successful RSV vaccine in the elderly might differ from a RSV vacci

113 amined the genetic stability of a PIV5-based RSV vaccine in vitro and in vivo We found that insertion

114 s the study of mucosal response to candidate RSV vaccines in frail elderly populations.

115 esults suggest that these VLPs are effective RSV vaccines in mice, in contrast to other nonreplicatin

116 -inactivated respiratory syncytial virus (FI-RSV) vaccine in 1966-1967 caused disastrous worsening of

117 need to be identified and addressed prior to RSV vaccine introduction to guide the measurement of imp

118 Vaccines are not available, and an RSV vaccine is particularly needed.

119 s and the elderly, but no safe and effective RSV vaccine is yet available.

120 nd young children, but no safe and effective RSV vaccine is yet available.

121 nactivated (FI) respiratory syncytial virus (RSV) vaccine led to exacerbated disease including pulmon

122 An effective RSV vaccine may offer benefits for these adults.

123 ction of neutralizing serum antibody with an RSV vaccine may potentially reduce disease severity in a

124 A live RSV vaccine might similarly decrease the risk of enhance

125 rly worldwide; however, there is no licensed RSV vaccine or effective drug treatment available.

126 An effective maternal RSV vaccine or monoclonal antibody could have a substant

127 need, we have failed to produce efficacious RSV vaccines or therapeutics.

128 in humans that ultimately lead to successful RSV vaccines or therapeutics.

129 -inactivated respiratory syncytial virus (FI-RSV) vaccine or RSV G glycoprotein results in enhanced p

130 lin-inactivated respiratory syncytial virus (RSV) vaccine preparations have been shown to cause enhan

131 challenges associated with a live attenuated RSV vaccine, providing, against the two leading viral ag

132 Overall, 48.5% and 30.9% of RSV vaccine recipients reported local and systemic solic

133 The development of a safe and efficacious RSV vaccine remains an important goal.

134 and efficacious respiratory syncytial virus (RSV) vaccine remains elusive.

135 The lack of a safe and effective RSV vaccine represents a major unmet medical need.

136 n is restricted to the respiratory tract, an RSV vaccine should elicit mucosal immunity at upper and

137 To test the hypothesis that FI-RSV vaccine stimulates the production of enhancing antib

138 A number of live attenuated RSV vaccine strains have been developed in which the sma

139 ction may offer a new, safe, and efficacious RSV vaccine strategy.

140 tegy for maternal immunization and for other RSV vaccine target populations such as older adults.

141 critical step in the development of nonlive RSV vaccines targeting RSV-naive children and infants.

142 udies are being conducted to identify a live RSV vaccine that is slightly more attenuated and less tr

143 s, this study indicates that live attenuated RSV vaccines that are immunogenic and phenotypically sta

144 The results suggest that RSV vaccines that induce antibodies that block G protein

145 nactivated (FI) respiratory syncytial virus (RSV) vaccine that is characterized by increased viral re

146 live attenuated respiratory syncytial virus (RSV) vaccines that contain combinations of known attenua

147 live attenuated respiratory syncytial virus (RSV) vaccines that have advanced to clinical trials have

148 r results suggest that the failure of the FI-RSV vaccine to induce a CD8 T cell response may have con

149 There are no licensed RSV vaccines to date.

150 The RSV vaccine was immunogenic but did not protect older ad

151 Development of an RSV vaccine was stymied when a clinical trial using a fo

152 The replication of the RSV vaccines was suppressed in the lower, but not the up

153 nactivated (FI) respiratory syncytial virus (RSV) vaccine, we studied the pulmonary inflammatory resp

154 response to influenza vaccination, and both RSV vaccines were well tolerated by 1169 participants.

155 A respiratory syncytial virus (RSV) vaccine will need to be administered by 1 mo of age

156 for implementation of a safe and immunogenic RSV vaccine within the context of global health and with

157 An ideal RSV vaccine would be effective for neonates, but the imm

158 An effective RSV vaccine would likely substantially reduce the burden

159 The blocking of cleavage should improve RSV vaccine yield, consequently reducing production cost